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We have read with interest the review by Jalan et al. [1] in which
they focus on the current understanding of acute-on-chronic liver
failure (ACLF) from the clinical, prognostic and pathophysiologic
perspectives. In addition, they indicate potential biomarkers and
therapeutic targets for intervention. The authors conﬁrm that the
condition remains undeﬁned, but that two consensus working
deﬁnitions for this syndrome exist: one put forward by the
Asia-Paciﬁc association for the study of liver disease (APASL)
and the other based on an EASL-AASLD single topic symposium.
Both deﬁnitions address the essential feature of acute hepatic
insult (APASL) or acute deterioration (EASL-AASLD) in patients
with pre-existing chronic liver disease. The authors emphasize
that ACLF is a syndrome that deﬁnes a subgroup of cirrhotic
patients. The authors show also a graphical interpretation of liver
function vs. time of the clinical concept of ACLF with its acute
insult in contrast to the chronic decompensation of cirrhosis.
The precipitating event, which can directly exacerbate liver
injury, and extrahepatic insults, which lead to liver decompensa-
tion, are also comprehensively discussed. Those are very impor-
tant considerations, which help distinguish both syndromes and
avoid confusion.
In our former review on ACLF [2], we also emphasize the
ambiguity and variability in the deﬁnition of ACLF and the need
for a uniform deﬁnition. The deﬁnitions and, consequently,
patient inclusion criteria within the included studies are not
unequivocal. One observation was that studies often do not indi-
cate whether pre-existing cirrhosis is essential for the deﬁnition
or not.
Several studies on ACLF reported the inclusion of patients
with underlying cirrhosis [3,4]. On the other hand, there is a
number of studies on ACLF including patients with chronic hep-
atitis B (CHB) without mentioning the presence of cirrhosis
[5,6] and others that mention that cirrhosis was not present in
all patients [7–9]. Some studies on ACLF [10,11] include both
chronic hepatitis and cirrhosis patients, and [11] report that
patients with chronic liver disease may have the outcome of liver
cirrhosis.
The study of Jalan et al. contributes to this ambiguity by pre-
senting only patients with cirrhosis at the ICU in Tables 2 and 3,
although the study states reliance on the EASL-AASLD deﬁnition,
which is not restricted to cirrhosis alone.
Since life-threatening deterioration by an acute event can
occur in both chronic hepatitis patients and cirrhotics, leading
to possible outcomes such as ACLF, it seems reasonable to include
both patients with cirrhosis, as well as patients with chronic hep-
atitis into the deﬁnition of ACLF. Variability in deﬁning and
including patients in the studies brings confusion. Not all patients
with CHB develop cirrhosis in the progression of disease, but theyJournal of Hepatology 2can develop ACLF. Should or should not the group of patients
with pre-existing CHB, that severely deteriorates by a precipitat-
ing event, be included in the deﬁnition of ACLF or should non-cir-
rhotic patients be considered as a separate group?
In any case, the establishment of a uniform deﬁnition of ACLF
is essential for understanding the pathophysiology, prognosis,
and treatment of the syndrome.013 vol. 59 j 190–199
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Reply to: ‘‘Acute-on-chronic liver failure – Its deﬁnition
remains unclear’’
Acute-on-chronic liver failure: Towards evidence-based
deﬁnition
To the Editor:
We would like to thank Dr. Wlodzimirow and colleagues for their
comments. We agree with them that a uniform deﬁnition of
Acute on Liver Failure (ACLF) is essential [1]. It is with this aim
that the CLIF Consortium initiated the CANONIC study, the results
of which provide the framework for a deﬁnition of ACLF and its
diagnostic criteria on the background of cirrhosis [2,3]. The issue
of liver failure that occurs on the background of chronic hepatitis
is more difﬁcult and without more data that include biopsies in
this group of patients, will remain very difﬁcult to deﬁne. Out
of nearly 1343 patients included in this study from 30 European
centers, almost all had cirrhosis; there were only a handful of
non-cirrhotic cases related to hepatitis B virus (HBV) reactivation.
Therefore, ﬁndings of the CANONIC study cannot be extrapolated
to patients with HBV-related ACLF. Nevertheless, we believe that
the PIRO (Predisposition, Injury, Response and Organ failure) con-
cept as described in our paper provides the framework generate
multimodal deﬁnitions which may include patients without
underlying cirrhosis [4,5]. It is clear that more data will be
needed to determine whether this group is at similar risk as
the patients with underlying cirrhosis. We encourage our col-
leagues who see this patient group to generate prospective data.
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